KRAS^G12C mutation in metastatic colorectal cancer: a new target

References

• 1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 14(2), 89–103 (2019).
  Medline CASGoogle Scholar
• 2. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol. Med. 13(1), 120–135 (2016).
  Medline CASGoogle Scholar
• 3. Won DD, Lee JI, Lee IK, Oh S-T, Jung ES, Lee SH. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer 17(1), 403 (2017).
  MedlineGoogle Scholar
• 4. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010, 150960 (2010).
  MedlineGoogle Scholar
• 5. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205(12), 858–862 (2009).
  Medline CASGoogle Scholar
• 6. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477), 548–551 (2013).
  Medline CASGoogle Scholar
• 7. Jones RP, Sutton PA, Evans JP et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116(7), 923–929 (2017).
  Medline CASGoogle Scholar
• 8. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 32(9), 1101–1110 (2021).
  Medline CASGoogle Scholar
• 9. Skoulidis F, Li BT, Dy GK et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384(25), 2371–2381 (2021).
  Medline CASGoogle Scholar
• 10. Fakih MG, Kopetz S, Kuboki Y et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23(1), 115–124 (2022).
  Medline CASGoogle Scholar
• 11. Weiss J, Yaeger RD, Johnson ML et al. LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann. Oncol. 32(Suppl. 5), S1294 (2021).
  MedlineGoogle Scholar
• 12. Goebel L, Müller MP, Goody RS, Rauh D. KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Med. Chem. 11(7), 760–770 (2020).
  Medline CASGoogle Scholar
• 13. Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6), 489–500 (2009).
  Medline CASGoogle Scholar
• 14. Prenen H, Fakih M, Falchook G et al. SO-39 evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: exploratory plasma biomarker analysis of CodeBreaK 100. Ann. Oncol. 33(Suppl. 4), S373 (2022).
  Google Scholar
• 15. Amodio V, Yaeger R, Arcella P et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10(8), 1129–1139 (2020).
  Medline CASGoogle Scholar
• 16. Ryan MB, Coker O, Sorokin A et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39(12), 110993 (2022).
  Medline CASGoogle Scholar
• 17. Kuboki Y, Yaeger R, Fakih M et al. 45MO sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort. Ann. Oncol. 33(Suppl. 9), S1445–S1446 (2022).
  Google Scholar
• 18. Yaeger R, Weiss J, Pelster MS et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. New Engl. J. Med. 388(1), 44–54 (2023).
  Medline CASGoogle Scholar
• 19. Yaeger R, Mezzadra R, Sinopoli J et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 13(1), 41–55 (2023).
  Medline CASGoogle Scholar
• 20. Canon J, Rex K, Saiki AY et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781), 217–223 (2019).
  Medline CASGoogle Scholar